{"id":"intravenous-fentanyl-guided-by-soc-nol","safety":{"commonSideEffects":[{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Chest wall rigidity"}]},"_chembl":{"chemblId":"CHEMBL1201159","moleculeType":"Small molecule","molecularWeight":"372.94"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fentanyl is a synthetic opioid that activates mu-opioid receptors throughout the brain and spinal cord, reducing pain perception and producing sedation. The NOL (Nociceptive Level) index is a multiparametric monitor that measures physiological responses to nociception (pain stimulus) in real-time, allowing clinicians to titrate fentanyl dosing more precisely to match the patient's actual nociceptive burden rather than relying on standard dosing protocols alone. This guided approach aims to optimize analgesia while minimizing opioid exposure and adverse effects.","oneSentence":"Intravenous fentanyl is a potent opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and sedation, with dosing guided by real-time monitoring of the nociceptive level (NOL index) combined with standard of care (SoC) assessment.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:49:46.491Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Intraoperative analgesia and sedation during general anesthesia"}]},"trialDetails":[{"nctId":"NCT03776838","phase":"PHASE4","title":"Impact of Nociceptive-Level (NOL) Intraoperative Guided Analgesia During Gynecological Laparoscopic Surgery Under General Anesthesia","status":"COMPLETED","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2018-11-30","conditions":"Gynecologic Laparoscopic Surgery, Hysterectomy, Oophorectomy","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Intravenous Fentanyl guided by SoC+NOL","genericName":"Intravenous Fentanyl guided by SoC+NOL","companyName":"Ciusss de L'Est de l'Île de Montréal","companyId":"ciusss-de-l-est-de-l-le-de-montr-al","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intravenous fentanyl is a potent opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and sedation, with dosing guided by real-time monitoring of the nociceptive level (NOL index) combined with standard of care (SoC) assessment. Used for Intraoperative analgesia and sedation guided by nociceptive monitoring.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}